U.S. Markets open in 6 hrs 11 mins

ResMed Inc. (RMD.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
32.47-0.10 (-0.31%)
At close: 4:10PM AEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.57
Open32.24
Bid32.47 x 0
Ask32.48 x 0
Day's Range32.05 - 32.60
52 Week Range23.10 - 32.60
Volume2,148,836
Avg. Volume1,384,536
Market Cap47.135B
Beta (5Y Monthly)0.28
PE Ratio (TTM)32.20
EPS (TTM)1.01
Earnings DateN/A
Forward Dividend & Yield0.20 (0.65%)
Ex-Dividend DateMay 12, 2021
1y Target Est12.43
  • ResMed (RMD) Hits a New 52-Week High: What's Driving It?
    Zacks

    ResMed (RMD) Hits a New 52-Week High: What's Driving It?

    Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

  • Why ResMed Stock Exploded Higher This Week
    Motley Fool

    Why ResMed Stock Exploded Higher This Week

    Through Thursday's close, shares of the medical equipment company ResMed (NYSE: RMD) were up by a healthy 10% so far this week. ResMed's stock is marching higher this week in response to Koninklijke Philips' (NYSE: PHG) decision to voluntarily recall approximately 3.5 million ventilation devices for treating sleep apnea. Philips is recalling the devices over the use of a polyester-based polyurethane (PE-PUR) sound abatement foam that could be toxic if inhaled or ingested.

  • 5 Reasons Why ResMed Gets Downgrade From BofA Securities
    Benzinga

    5 Reasons Why ResMed Gets Downgrade From BofA Securities

    Although ResMed Inc’s (NYSE: RMD) long-term outlook is positive, the market seems to have over-reacted to rival Koninklijke Philips NV’s (NYSE: PHG) recall notification of certain sleep and respiratory care devices for the U.S., according to BofA Securities. The ResMed Analyst: Lyanne Harrison downgraded the rating for ResMed from Neutral to Underperform, while raising the price target from $216 to $221. The ResMed Thesis: Although the company is poised to benefit from Philips’s recall, the magn